Research and Development of Molecular Mechanisms and Key Technologies for Prevention and Control of Inflammatory Diseases of the Female Genital Tract

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600122631

Enrollment

Unknown

Registered

2026-04-15

Start date

2025-11-26

Completion date

Unknown

Last updated

2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious Diseases of the Female Genital Tract

Interventions

Bacterial vaginosis, aerobic vaginitis, atrophic vaginitis group:none

Vulvovaginal Candidiasis Group:none

Pelvic Inflammatory Disease Group:none

Health group:none

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria for healthy women: (1) Women of childbearing age; (2) Without fever; (3) With sexual history; (4) Not using contraceptives; (5) No use of estrogen or progesterone after the last menstrual period; (6) Excluding concurrent other vulvar/vaginal/cervical lesions; (7) No vaginal bleeding or discharge within 48 hours; No vaginal irrigation within 48 hours; (8) No sexual activity or vaginal medication (including suppositories, wiping) within 3 days; (9) No antibiotic or antifungal drug (such as cephalosporins, penicillins, fluconazole, etc.) use within 1 month; (10) Complete cervix, no history of cervical surgery in the past 1 year. Inclusion criteria for women with reproductive tract inflammatory diseases: (1) Women of childbearing age; (2) Those diagnosed with reproductive tract inflammation based on symptoms, signs, and laboratory tests; (3) With sexual history; (4) Not using contraceptives; (5) No use of estrogen or progesterone after the last menstrual period; (6) Excluding concurrent other vulvar/vaginal/cervical lesions; (7) No vaginal irrigation within 48 hours; (8) No sexual activity or vaginal medication (including suppositories, wiping) within 3 days; (9) No antibiotic or antifungal drug (such as cephalosporins, penicillins, fluconazole, etc.) use within 1 month; (10) Complete cervix, no history of cervical surgery in the past 1 year.

Exclusion criteria

Exclusion criteria: Exclusion criteria for normal females: (1) Having reproductive system inflammation at the time of sampling; (2) Having a history of bacterial vaginosis, vulvovaginal candidiasis, urinary tract infection, sexually transmitted diseases (especially chlamydia infection, gonorrhea, syphilis, condyloma acuminatum, genital herpes, trichomonas vaginitis, HIV) within 2 months; (3) Having a history of chronic diseases such as immune disorders, diabetes, and malignant tumors. Exclusion criteria for females with reproductive tract inflammatory diseases: Those who do not meet the inclusion criteria for reproductive tract inflammatory diseases.

Design outcomes

Primary

Measure	Time frame
Sequencing of the bacterial community in reproductive tract secretions;Metabolomics of peripheral blood and inflammatory tissues;	—

Secondary

Measure	Time frame
Peripheral blood and inflammatory tissue proteomics;Blood routine and other biochemical and metabolic indicators;	—

Countries

China

Contacts

Public ContactLyu Weiguo

Women's Hospital School of Medicine Zhejiang University

lbwg@zju.edu.cn+86 571 8999 5250

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026